Document Detail

Effects of dihydropyridine calcium antagonists on albuminuria in patients with diabetes.
MedLine Citation:
PMID:  8690823     Owner:  NLM     Status:  MEDLINE    
The present study was designated to assess the effects of two different dyhydropyridine calcium antagonists (DHPCAs) on proteinuria in patients with noninsulin-dependent diabetes mellitus (NIDDM). The hypothesis that similar levels of blood pressure reduction with two different DHPCAs produce similar degrees of proteinuria reduction was tested. In a prospective randomized study, 14 patients with NIDDM, hypertension, proteinuria, and renal insufficiency were given either isradipine (n = 7) or nifedipine XL (n = 7) for 6 months. After a 2-week washout period, patients were crossed over to the other drug and observed for an additional 6 months. Drugs were titrated to lower arterial pressure to < 140/90 mmHg. Patients also instructed to follow a low-sodium diet at the initial visit. Blood pressure and 24-hour urine values for creatinine clearance, albuminuria, proteinuria, and sodium were assessed monthly. At the end of the initial and crossover treatment periods, there were no significant reductions in the level of albuminuria from baseline with either drug. Sodium excretion was < 110 mEq/L with each drug tested. The results of this study support the concept that DHPCAs do not reduce proteinuria in patients with type II diabetes. This failure to reduce albuminuria and proteinuria occurred despite adequate blood pressure reduction and an effort at dietary sodium restriction.
K Abbott; A Smith; G L Bakris
Related Documents :
1259123 - Effects of sodium nitroprusside during the excision of phaeochromocytoma.
11313 - Effect of disintegrant type upon the relationship between compressional pressure and di...
22371793 - Effects of coenzyme q10 supplementation on activities of selected antioxidative enzymes...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Journal of clinical pharmacology     Volume:  36     ISSN:  0091-2700     ISO Abbreviation:  J Clin Pharmacol     Publication Date:  1996 Mar 
Date Detail:
Created Date:  1996-08-29     Completed Date:  1996-08-29     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0366372     Medline TA:  J Clin Pharmacol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  274-9     Citation Subset:  IM    
Department of Medicine, Brook Army Medical Center, San Antonio, Texas, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Albuminuria / drug therapy*,  urine
Calcium Channel Blockers / adverse effects,  therapeutic use*
Cross-Over Studies
Diabetes Mellitus, Type 2 / drug therapy*,  urine
Diet, Sodium-Restricted
Hypertension / drug therapy
Isradipine / adverse effects,  therapeutic use*
Nifedipine / adverse effects,  therapeutic use*
Prospective Studies
Reg. No./Substance:
0/Calcium Channel Blockers; 21829-25-4/Nifedipine; 75695-93-1/Isradipine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  No evidence of a direct venodilatory effect of furosemide in healthy human subjects.
Next Document:  Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin ...